Clarifications about add-on payments for fidaxomicin

American Journal of Health-System Pharmacy

Volumn 70, Issue 12, 2013, Pages 1015-1016

  Shah, Hemal ^a,b   Tallman, Anna M ^b   Capurso, Shelley ^a,b  

^a Texas Children's Health Plan   (United States)

^b Optimer Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ADD ON THERAPY; EMERGENCY CARE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LETTER; MEDICAID; MEDICARE; PROSPECTIVE PAYMENT; REIMBURSEMENT; ECONOMICS; GOVERNMENT; STANDARD; UNITED STATES;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CENTERS FOR MEDICARE AND MEDICAID SERVICES (U.S.); HUMANS; REIMBURSEMENT MECHANISMS; UNITED STATES;

EID: 84886381598     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120683     Document Type: Letter

References (4)

1. Thompson CA. CMS to compensate hospitals for inpatient use of fidaxomicin, glucarpidase. Am J Health-Syst Pharm. 2012; 69:1618-9. News.
2. Centers for Medicare and Medicaid Services. CMS-1588-F. Fiscal year 2013 inpatient prospective payment systems final rule. www.gpo.gov/fdsys/pkg/FR-2012-08-31/pdf/2012-19079.pdf (accessed 2012 Oct 16).
3. Clyde AT, Bockstedt L, Farkas JA et al. Experience with Medicare's new technology add-on payment program. Health Aff. 2008; 27:1632-41.
4. Centers for Medicare and Medicaid Services. Pub 100-04. Fiscal year (FY) 2013 inpatient prospective payment system (IPPS), long term care hospital (LTCH) PPS changes. www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R2627CP.pdf (accessed 2013 Jan 23).